These are the primary sources cited across our articles. We link to regulatory agencies, peer-reviewed studies, and established clinical references so you can check the claims yourself. A listed source is a citation, not an endorsement of our practice. Last updated July 13, 2026.
Botox & neuromodulators
- A Practical Guide to Botulinum Toxin Procedures, Rebecca Small and Dalano Hoang (Wolters Kluwer / Lippincott Williams & Wilkins). Standard clinical procedure reference.
- BOTOX Cosmetic prescribing information and label (FDA DailyMed)
- A growing neuromodulator market and the Daxxify approval (Practical Dermatology)
- DaxibotulinumtoxinA (Daxxify) overview (Skin Therapy Letter)
- OnabotulinumtoxinA onset of effect study (PubMed Central)
- Daxxify SAKURA phase 3 trial data (PubMed Central)
- RelabotulinumtoxinA (Relfydess) FDA application acceptance (Galderma)
- Baby Botox explained (Cleveland Clinic)
- Peer-reviewed evaluation of AI injection planning (Lehigh Valley Health Network)
- Injection-device dosing accuracy study (PubMed Central)
Weight loss & GLP-1 medications
- FDA proposal on compounded semaglutide, tirzepatide, and liraglutide (Medical News Today)
- FDA approves first oral GLP-1 pill for weight loss (The American Journal of Managed Care)
- American Gastroenterological Association clinical guideline on GLP-1 therapy (PubMed)
Hormones & peptides
- Experts urge FDA to revisit testosterone therapy labeling (Urology Times)
- Endocrine Society clinical practice guideline on testosterone therapy (Journal of Clinical Endocrinology & Metabolism)
- Pharmacy Compounding Advisory Committee meeting on BPC-157 (July 2026) (U.S. FDA)
- FDA reviews compounding for previously flagged peptides (BioSpace)
IV therapy & NAD+
- U.S. IV hydration therapy market report (Grand View Research)
- NAD infusions, supplements, and the longevity science (NPR)
Ketamine therapy
- Fourth temporary extension of telemedicine flexibilities for controlled substances (December 2025) (U.S. Federal Register)
- DEA extends telemedicine flexibilities for ketamine prescribing (Healthcare Law Insights)
- Telehealth ketamine and real-time monitoring (STAT News)
- Injectable ketamine drug shortage listing (ASHP)
Exosome therapy & hair loss
- Consumer alert on regenerative medicine products, including stem cells and exosomes (U.S. FDA)
- 2023 systematic review of exosomes for hair restoration (PubMed)
- 2025 systematic review of exosomes and hair regeneration (Clinical, Cosmetic and Investigational Dermatology)
- Androgenetic alopecia, including FDA-approved treatments (StatPearls, NCBI)
Practice and industry context
- Concierge medicine market sizing (Towards Healthcare)
Links open on third-party sites we do not control. Our articles are for general education and are not medical advice. Speak with a qualified physician about your specific situation.